Cochlear Limited (ASX:COH) Announces Half-Year 2024 Financial Results

Financial Performance

Cochlear Limited reported a 5% increase in sales revenue to $1,170 million for the half year ended December 2024, reaching $1,169.9 million. Underlying net profit rose by 7% to $206 million, maintaining an 18% net profit margin. The company’s gross margin remained steady at 75%, and operating expenses grew by 10% to $614.4 million. Strong balance sheet and cash flow generation supported an 8% increase in the interim dividend to $2.15 per share.

Operational Achievements

The increase in revenue was driven by a 13% rise in cochlear implant revenue and a 22% growth in acoustics revenue, offset by a 12% decline in services revenue. Cochlear implant units grew by 5% to 25,390, supported by a higher mix of private pay units in emerging markets. Acoustics revenue benefited from the strong uptake of the Cochlear™ Osia® Implant and geographic expansion into new countries. The company is preparing to release next-generation cochlear implants and the Nucleus® Kanso® 3 Sound Processor from mid-2025, subject to regulatory approvals.

Future Outlook

For FY25, Cochlear expects underlying net profit to be at the lower end of the $410-430 million guidance range, considering lower services revenue and increased cloud-related investments. The company aims to help over 50,000 people hear with cochlear or acoustic implants and anticipates continued market growth and strategic investments in R&D and market expansion.

Dividends

An interim dividend of $2.15 per share was declared, an 8% increase from the previous year, representing a payout of 68% of underlying net profit. The dividend is franked at 80%, with the ex-dividend date set for 20 March 2025 and payment expected on 14 April 2025.

View Original Announcement

here

Motley Fool contributor Matt Burgess has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.